-
EP0625979
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP0625979
| EP0625979 - AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.10.1996 Database last updated on 02.09.2024 | Most recent event Tooltip | 18.10.1996 | Application deemed to be withdrawn | published on 04.12.1996 [1996/49] | Applicant(s) | For all designated states SMITHKLINE BEECHAM PLC New Horizons Court Brentford Middlesex TW8 9EP / GB | [N/P] |
| Former [1994/48] | For all designated states SMITHKLINE BEECHAM PLC New Horizons Court Brentford, Middlesex TW8 9EP / GB | Inventor(s) | 01 /
ORLEK, Barry, Sidney SmithKline Beecham Pharmaceuticals Coldharbour Road The Pinnacles Harlow Essex CM19 5AD / GB | 02 /
BROWN, Thomas, Henry SmithKline Beecham Pharmaceuticals Coldharbour Road The Pinnacles Harlow Essex CM19 5AD / GB | 03 /
COOPER, David, Gwyn Smithkline Beecham Pharmaceuticals Coldharbour Road The Pinnacles Harlow Essex CM19 5AD / GB | [1994/48] | Representative(s) | Waters, David Martin GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | [N/P] |
| Former [1994/48] | Waters, David Martin, Dr. Smithkline Beecham plc Corporate Intellectual Property SB House Great West Road Brentford, Middlesex TW8 9BD / GB | Application number, filing date | 93902471.7 | 27.01.1993 | [1994/48] | WO1993GB00175 | Priority number, date | GB19920001749 | 28.01.1992 Original published format: GB 9201749 | [1994/48] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO9315073 | Date: | 05.08.1993 | Language: | EN | [1993/19] | Type: | A1 Application with search report | No.: | EP0625979 | Date: | 30.11.1994 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.08.1993 takes the place of the publication of the European patent application. | [1994/48] | Search report(s) | International search report - published on: | EP | 05.08.1993 | Classification | IPC: | C07D453/02, A61K31/395, C07D487/08, C07D471/08 | [1994/48] | CPC: |
C07D471/08 (EP);
A61K31/435 (EP);
A61K31/47 (EP);
A61K31/55 (EP);
A61P25/04 (EP);
A61P25/28 (EP);
A61P3/00 (EP);
A61P3/14 (EP);
A61P31/12 (EP);
A61P37/04 (EP);
A61P9/08 (EP);
A61P9/10 (EP);
| Designated contracting states | BE, CH, DE, FR, GB, IT, LI, NL [1994/48] | Title | German: | AZABICYCLISCHE VERBINDUNGEN ALS CALCIUM-KANAL-BLOCKER | [1994/48] | English: | AZABRICYCLIC COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | [1994/48] | French: | COMPOSES AZABICYCLIQUES SERVANT D'ANTAGONISTES DES CANAUX CALCIQUES | [1994/48] | File destroyed: | 20.04.2002 | Entry into regional phase | 20.06.1994 | National basic fee paid | 20.06.1994 | Designation fee(s) paid | 20.06.1994 | Examination fee paid | Examination procedure | 09.07.1993 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 20.06.1994 | Examination requested [1994/48] | 30.10.1995 | Despatch of a communication from the examining division (Time limit: M06) | 10.05.1996 | Application deemed to be withdrawn, date of legal effect [1996/49] | 05.07.1996 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [1996/49] | Fees paid | Renewal fee | 09.01.1995 | Renewal fee patent year 03 | 08.01.1996 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]EP0412797 (MERCK SHARP & DOHME [GB]); | [X]EP0327155 (MERCK SHARP & DOHME [GB]); | [X]WO9114686 (NOVO NORDISK AS [DK]); | [X]EP0416754 (MERCK SHARP & DOHME [GB]); | [XP]EP0470668 (MERCK SHARP & DOHME [GB]); | [XP]EP0473442 (MERCK SHARP & DOHME [GB]); | [XP]EP0492902 (MERCK SHARP & DOHME [GB]); | [XP]EP0492903 (MERCK SHARP & DOHME [GB]); | [XP]EP0492904 (MERCK SHARP & DOHME [GB]); | [XP]EP0497415 (AKZO NV [NL]); | [XP]WO9215579 (RHONE POULENC RORER INT [US]) | [A] - CHEMICAL ABSTRACTS, vol. 115, 1991, Columbus, Ohio, US; abstract no. 149760y, V.E. DEGTYAR ET AL. 'Common characteristics of calcium-channel and muscarinic-cholinergic receptor inhibitors.' page 18 ; |